AbbVie Entered into a Clinical Trial Collaboration Agreement with SpringWorks to Evaluate ABBV-383 + Nirogacestat for Multiple Myeloma
Shots:
- The companies collaborated to evaluate the safety, tolerability & preliminary efficacy of SpringWorks’ nirogacestat + AbbVie’s (ABBV-383) in a P-Ib study in patients with r/r MM. The study is expected to start in H1’22
- AbbVie will sponsor & conduct the P-Ib study & will assume all costs associated with the study other than expenses related to the manufacturing of nirogacestat & IPRs
- Additionally, both companies will also form a joint committee to manage the clinical study. Nirogacestat received ODD from the US FDA & EC for desmoid tumors & soft tissue sarcoma & also received FTD & BTD for progressive, unresectable, recurrent, or refractory desmoid tumors or deep fibromatosis
Ref: Globe Newswire | Image: abbvie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com